The Society of Toxicology’s SOT 2025 meeting in Orlando, Florida, held from March 20-22, was a unique gathering that highlighted both the ongoing challenges and the evolving opportunities within the toxicology and bioanalytical fields. As a Bioanalytical CRO providing critical dose formulation testing and toxicology studies…

Polymerase Chain Reaction (PCR) has revolutionized molecular biology by enabling the rapid and precise amplification of DNA sequences. Since its invention by Kary Mullis in the 1980s, PCR has become an indispensable tool in both research and diagnostic applications. From identifying genetic disorders to detecting infectious diseases, PCR’s versatility has…

KCAS Bio is excited to announce its participation in the upcoming 19th Workshop on Recent Issues in Bioanalysis (WRIB), taking place April 7-11, 2025, in New Orleans, Louisiana. As a long-standing attendee and active contributor at WRIB, KCAS Bio is proud to continue its tradition of…

What Are Neutralizing Antibody (NAb) Assays? Neutralizing antibodies (NAbs) are a subset of anti-drug antibodies (ADAs) that play an important role in evaluating the immunogenicity, safety, and efficacy of a drug product. While most drugs carry a low risk of eliciting NAbs and do not require a validated NAb…

Last month, Elodie, Magali, and I found ourselves in Lisbon—not for a spring getaway (though the weather was a delightful preview of the season) and certainly not for ultra-trail training (although the city’s hills did give our calves a solid workout!). Instead, we were there for EIP, an event…

The bioanalysis world has exploded with the need for molecular assays (qPCR, dPCR, NGS, Hybridization technologies) due to the demand for both biodistribution/PK and PD/BM analysis of various drug modalities. Many of these molecular assays have been around for decades and are now routine methods. CLIA and reference labs have…

When it comes to developing new therapies for inflammatory bowel diseases (IBD), having robust and reliable bioanalytical support is crucial. From the early stages of drug discovery to Phase III clinical trials, our comprehensive bioanalytical solutions are designed to enhance and accelerate your drug development journey in a GCP…

ADCs represent a promising class of targeted therapies, and understanding the intricacies of their analysis is crucial for their successful development. In this blog, we address common questions to guide you through the various considerations involved in ADC research and testing. We will cover key topics related to the…

Understanding the intricate relationship between drugs and the human body is crucial for effective medical treatments. Two fundamental concepts in pharmacology – pharmacokinetics and pharmacodynamics – play pivotal roles in this understanding. This blog post will delve into these concepts, exploring their differences and significance in drug development and clinical…

Cell-based immunotherapies like Chimeric Antigen Receptor (CAR)-T cell therapy have been transforming the treatment of hematologic malignancies for more than a decade. Several groundbreaking studies (1) have led to a growing interest in applying these cell-based therapies to other T and B cell-mediated diseases.  One emerging application of CARs is…

If you have trained in the field of immunology, it may not be uncommon to emerge with a self-characterization as either a “B-cell immunologist” or a “T-cell immunologist.” Historically, this distinction arose from years of specialization and the degrees of separation between T-cell and B-cell biology research.  Approaches to therapeutic…

What is a generic PK assay? A generic pharmacokinetic (PK) assay, also referred to as a universal PK assay for New Biologic Entities (NBE), is used to measure circulating human biotherapeutics—primarily antibody-based—post-administration across various non-human matrices. These assays are particularly beneficial when drug-specific reagents, such as anti-idiotype antibodies, are…